AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2012
Nov 7, 2012
34113_dirs_2012-11-07_3cf540b1-ad5c-486b-a73b-30b3c00a2dec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2012-11-07
Reporting Person: Galli Stephen J (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 17674 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $6.00 | 2022-04-30 | Common Stock (5927) | Direct | |
| Stock Option (Right to Buy) | $1.25 | 2021-09-01 | Common Stock (40000) | Direct |
Footnotes
F1: On April 30, 2012, the Board of Directors approved a grant to the Reporting Person of stock options to purchase an aggregate of 5,927 shares of Common Stock, fully vested and exercisable as of the date of grant.
F2: The first 10,000 options vested on December 1, 2011 and the remaining options vested in equal quarterly amounts on each of March 1, 2012, June 1, 2012 and September 1, 2012.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Feb 20
Regulatory Filings
2026
Feb 17
Regulatory Filings
2026
Feb 11